Acar, Ali

Loading...
Profile Picture
Name Variants
A., Ali
Acar, Ali
A.,Acar
A.,Ali
Ali, Acar
A., Acar
Acar,A.
Job Title
Profesör Doktor
Email Address
ali.acar@atilim.edu.tr
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

4

Articles

4

Citation Count

2

Supervised Theses

0

Scholarly Output Search Results

Now showing 1 - 4 of 4
  • Article
    Citation Count: 0
    Evaluation of COVID-19 Cases Who Received Immunosuppressive Therapy at a Tertiary Care Hospital
    (Doc design informatics Co Ltd, 2022) Acar, Ali; Acar, Ali; Bulut, Dilek; Celik, Sebahattin; Oguz, Emin; Basic Sciences
    Objective: Immunosuppressive drugs are included in the treatment protocols of severe COVID-19 cases that may present with cytokine storm. In this study, we aimed to examine the characteristics of COVID-19 patients who received immunosuppressive therapy Methods: Patients diagnosed with COVID-19 and followed in the quarantine wards of our hospital between 01.03.2020-24.05.2020 were included in the study. Patient information was obtained retrospectively from patient files and discharge reports, and 263 COVID-19 patients-aged 18 and over-were included in the study. Results: The median age of the patients who received immunosuppressive therapy was 60.74 +/- 1.96, and 39.6% of them were women. The average symptom duration of the patients examined in the study at the time of admission to the hospital was 4.59 +/- 0.29 days. There was a significant difference in age, lymphocyte count, neutrophil/lymphocyte ratio, C-reactive protein, ferritin, D-Dimer, blood oxygen saturation, fever after antiviral therapy, qSOFA score, and total hospital stay between the two groups that received and did not receive immunosuppressive therapy (p<0.05). The need for immunosuppressive therapy increased 15.9 times over the age of 40, 15.6 times in the presence of diffuse involvement on thoracic CT, 6.6 times in the presence of chronic disease, 2.7 times in the presence of thrombocytopenia, and 1.7 times in the presence of lymphopenia (p <0.05).Conclusions: We observed that patients whose immunosuppressive therapy was added to their treatment protocols were admitted to the hospital later than others, had more prevalent involvement in thorax CT, high acute phase reactants, low SPO2, and more than one underlying disease.
  • Article
    Citation Count: 0
    The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19
    (Doc design informatics Co Ltd, 2023) Acar, Ali; Özger, Hasan Selçuk; Acar, Ali; Keskin, Ayşegül Seremet; Binay, Umut Devrim; Ünlü, Gülten; Diseases, The Adult Immunization Study Group Of The Turkish Society Of Clinical Microbiology And Infectious; Basic Sciences
    Objective: We aimed to investigate the vaccination status and the risk factors for the in- tensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpa- tients, divided into two groups as ‘fully’ and ‘partially’ vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mel- litus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the pre- dominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group’s need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vacci- nated were associated with the need for ICU support. Therefore, all countries should con- tinuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.
  • Article
    Citation Count: 2
    Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection
    (Elsevier, 2023) Acar, Ali; Bulut, Dilek; Acar, Ali; Basic Sciences
    Background and study aims: The current study aimed to investigate the frequency of hepatic steatosis in chronic hepatitis B (CHB) patients and determine the possible risk factors associated with its presence.Patients and methods: This cross-sectional study retrospectively evaluated the medical records of 255 adult CHB patients visiting an infectious disease outpatient clinic. Patients with hepatitis B surface anti-gen positivity for >6 months and those who did not receive antiviral therapy were included in the study. The presence and stage of hepatic steatosis were determined through hepatobiliary ultrasonography.Results: The mean age of the patients was 40.6 +/- 12.7 years. Hepatic steatosis was detected in 44.4 % of the patients through ultrasound imaging. Our findings showed that the detected steatosis prevalence in our patients with CHB was significantly higher compared to the highest prevalence of non-alcoholic steatohepatitis found in the general Turkish population (19.9 %) [RR 2.23 (1.75-2.86), p < 0.001]. CHB patients with steatosis had significantly higher age, triglyceride, and gamma-glutamyl transferase levels than those without steatosis (p < 0.05). No significant association was found between the presence of steatosis, sex, liver function test results, and platelet, alkaline phosphatase, cholesterol, alpha fetoprotein, or HBV-DNA levels. No significant relationship was found between aspartate aminotransferase (AST)/platelet ratio index (APRI) and steatosis was examined (p > 0.05). Post-hoc analysis showed a sig-nificant relationship between HBV-DNA levels and ALT, AST, and APRI scores.Conclusion: Our data showed that hepatic steatosis is more common in CHB patients than in the general population. Older age and high triglyceride levels increased the risk of hepatic steatosis in CHB patients, consequently increasing GGT levels, which are indicative of liver damage, in these patients.(c) 2022 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.
  • Article
    Citation Count: 0
    Impact of the COVID-19 Pandemic on Diabetic Foot Patients A Shift in the Infectious Agent Profile Toward Nonfermentative Gram-Negative Bacilli
    (American Podiatric Medical Association, 2024) Tülek, Necla; Saltoğglu,N.; Acar, Ali; Turhan,Ö.; Serin,E.N.; Yapar,D.; Kaya,S.D.; Basic Sciences
    Background: Diabetes foot infection is a very important public health problem that causes serious health problems, mortality, and high health expenditures, and is one of the most important complications of diabetes mellitus. There are concerns that approaches such as limited personal visits to doctors, avoidance of hospitals, and restrictions on nonemergency surgical procedures during the coronavirus disease of 2019 pandemic pose a threat to those with diabetic foot problems, including diabetic foot ulcers (DFUs), ischemia, and infection, resulting in increased limb loss and mortality. Methods: This multicenter, retrospective, cross-sectional study was conducted in 14 tertiary care hospitals from various regions of Turkey. A total of 1,394 patient records were evaluated, 794 of which were between January 1, 2019, and January 30, 2020 (prepandemic [Pre-P]), and 605 of which were between February 1, 2020, and February 28, 2021 (pandemic period [PP]). Results: During the PP, diabetic foot patient follow-up decreased by 23.8%. In addition, the number of hospitalizations attributable to DFU has decreased significantly during the PP (P = .035). There was no difference between the groups regarding patient demographics, medical history, DFU severity, biochemical and radiologic findings, or comorbidities, but the mean duration of diabetes mellitus years was longer in patients in the Pre-P than in those in the PP (15.1 years versus 13.7 years). There was no difference between the two groups in terms of major complications such as limb loss and mortality, but infection recurrence was higher in the PP than in the Pre-P (12.9% versus 11.4%; P < .05). The prevalence of nonfermentative gram-negative bacteria as causative agents in DFU infections increased during the PP. In particular, the prevalence of carbapenem-resistant Pseudomonas spp. increased statistically during the PP. Conclusions: The rapid adaptation to the pandemic with the measures and changes developed by the multidisciplinary diabetic foot care committees may be the reasons why there was no increase in complications because of DFU during the pandemic in Turkey. © 2024, American Podiatric Medical Association. All rights reserved.